Baxter(US:BAX) Prnewswire·2025-11-06 13:45Core Viewpoint - Baxter International, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding the safety and efficacy of its Novum LVP product, which reportedly has systemic defects leading to serious patient risks [1]. Group 1: Allegations and Issues - The lawsuit claims that Baxter's Novum LVP product suffered from systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, posing risks of serious injury or death to patients [1]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but failed to adequately address the issues through customer alerts [1]. - The company’s statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs are claimed to be materially false and misleading [1]. Group 2: Class Action Details - The class period for the lawsuit is defined as February 23, 2022, to July 30, 2025, and shareholders are encouraged to register for participation [2]. - The deadline for shareholders to seek lead plaintiff status is December 15, 2025, with no cost or obligation to participate in the case [2]. Group 3: Law Firm's Role - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].